Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
7.28
-0.55 (-7.02%)
At close: Feb 21, 2025, 4:00 PM
7.38
+0.10 (1.37%)
After-hours: Feb 21, 2025, 5:41 PM EST
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Verve Therapeutics stock have an average target of 25.75, with a low estimate of 14 and a high estimate of 40. The average target predicts an increase of 253.71% from the current stock price of 7.28.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2024.
Analyst Ratings
The average analyst rating for Verve Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $29 → $32 | Strong Buy | Maintains | $29 → $32 | +339.56% | Nov 6, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $20 → $17 | Buy | Maintains | $20 → $17 | +133.52% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $14 | Strong Buy | Maintains | $15 → $14 | +92.31% | Nov 6, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $30 → $29 | Strong Buy | Maintains | $30 → $29 | +298.35% | Aug 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +106.04% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
24.28M
from 11.76M
Increased by 106.46%
Revenue Next Year
16.51M
from 24.28M
Decreased by -32.00%
EPS This Year
-2.55
from -3.12
EPS Next Year
-2.96
from -2.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 31.1M | 28.8M | 25.8M | |||
| Avg | 24.3M | 16.5M | 10.2M | |||
| Low | 18.6M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 164.5% | 18.8% | 56.5% | |||
| Avg | 106.5% | -32.0% | -38.3% | |||
| Low | 58.4% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.44 | -2.39 | -2.31 | |||
| Avg | -2.55 | -2.96 | -3.00 | |||
| Low | -2.76 | -3.54 | -3.70 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.